News Immunocore announces the presentation of initial data from the Phase 1 ImmTAV® trial for chronic Hepatitis B at the EASL International Liver Congress™ Continue Reading Previous Aleafia Health to Announce Fiscal Year 2022 Fifth Quarter and Year End Results – UpdateNext Arbutus Presents New Data on AB-729, AB-836 and AB-101 at the EASL International Liver Congress™ 2022 and Provides AB-836 Clinical Update Related Stories News Hoppn Launches Similar Colors, Bringing Color-Matched Product Recommendations to Shopify Product Pages News IntentKey Adds Major National Brands and Expands Distribution Through Technology Integrations News Shufti Launches Glocal Trust OS, Connecting Business-Wide Information with User Risk Signals for Context-Aware Decisions News Ortelan’s Praus Tops Models From Four Frontier AI Labs on JUP-Eval, a New Open Benchmark for AI Judgment News iQor Inaugurates New Cairo Delivery Center to Expand AI-Powered Customer Experience Operations News Walls.io Launches AI Moderation: A 24/7 Content Moderator that Follows Your Rules